VIVO Cannabis(TM) Announces Launch of Beacon Medical(TM) High-Dose CBD Oil and Pediatric Compassionate Care Program

Toronto, Ontario–(Newsfile Corp. – November 23, 2021) – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (“VIVO” or the “Company“), a leading provider of medical cannabis products and patient services, and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited (“Canna Farms”) and ABcann Medicinals Inc., today announced the launch of its newest medical cannabis product formulation: high-dose cannabidiol (CBD) oil under its Beacon Medical™ brand.

Beacon Medical™ 2:100 high-dose CBD oil is a distillate-based cannabis oil containing 100 mg CBD and less than 2 mg tetrahydrocannabinol (THC). The entire family of Beacon Medical™ oil products are formulated using a non-GMO, food-grade medium-chain triglycerides (MCT) carrier oil which results in the final product being both scentless and flavourless in taste.

“With our commitment to the medical cannabis market, the team at VIVO aspires to deliver premium cannabinoid-based medical products to our patients, and the Beacon Medical™ CBD+ | O has been launched in response to patient insights our team has collected over time,” commented Ray Laflamme, Canna Farms’ Co-Founder and VIVO’s Chief Executive Officer. “We recognize that many of our patients are looking for products that meet their individualized needs, and this latest addition to the Beacon Medical family of products is an excellent high potency CBD option for patients and it will be available to patients, doctors, and hospitals alike.”

Beacon CBD +|O [2:100] Extra-strength CBD oil to help patients achieve their health objectives

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/3063/104861_d6d7d616944e29cd_002full.jpg

VIVO simultaneously announced the launch of a Pediatric Compassionate Care Program to support caregivers and families requiring medical cannabis to treat a variety of pediatric conditions. Eligible patients will receive substantial discounts off all Beacon Medical™, Canna Farms™, Fireside™ and Lumina™ CBD products.

VIVO stands strong on its patient-first approach ensuring choice, access, and consistent supply for patients. Beacon Medical™ products are available exclusively in select medical markets in Canada, Australia & Germany.

This newly launched Beacon Medical™ high CBD oil is available through the Canna Farms e-commerce medical marketplace for Canadian medical clients. Patients requiring support with registration or placing orders can contact VIVO’s Customer Care Team at 1 (855) 882-0988 or care@vivocannabis.com.

About VIVO Cannabis™

VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities. VIVO has a collection of medical, health and wellness brands, each targeting different customer segments, including Canna Farms™, Beacon Medical™, Fireside™, and Lumina™. Harvest Medicine™, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 150,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com.

For further information:

VIVO Investor Relations
+1 416-848-9839
ir@vivocannabis.com

Instagram: https://www.instagram.com/vivo_cannabis/
Facebook: https://www.facebook.com/vivocanna/
Twitter: https://twitter.com/vivo_cannabis
LinkedIn: https://www.linkedin.com/company/vivo-cannabis-inc/

Disclaimer for Forward-Looking Information

Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward‐looking statements. No assurance can be given that any of the events anticipated by the forward‐looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully along with the more extensive risk factors included in the Company’s most recent management’s discussion and analysis available on SEDAR, in evaluating the forward‐looking statements contained in this news release and are cautioned not to place undue reliance on such forward‐looking statements, which are qualified in their entirety by these cautionary statements. The forward‐looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward‐looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/104861